ArticleCPT: pharmacometrics & systems pharmacology2023

Sabatolimab (MBG453) model-informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors.

Siyan Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.